$3.00
▼ -1.0% Today
as of Aug 5, 16:45 ET
Last 30 days
Recent Press Releases & News
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
Overview
52-week range
$2.56
$7.73
9% of range
Avg surprise (last 3)
+23.1%
Avg reaction (last 2)
-3.1%
0% positive
Latest IV / EM
74%
EM ±9.8% · $3 · Aug 14
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.18 | $-0.25 | +28.0% | +30.8% | -1.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.21 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.27 | $-0.32 | +15.6% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.26 | $-0.35 | +25.7% | — | -4.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.32 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.35 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.34 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.39 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.32 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.15 | -$0.27 | +44.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $5,000 | $5,000 | $5,000 | — | $5,000 | $5,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-24M | — | $-21M | $-23M | $-22M | — | $-25M | $-27M |
| Net income | $-23M | — | $-19M | $-22M | $-20M | — | $-23M | $-25M |
| EPS (diluted) | $-0.18 | — | $-0.21 | $-0.27 | $-0.26 | — | $-0.32 | $-0.35 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $98M | $44M | $61M | $183M | $49M | $37M | $31M | $57M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $335M | $278M | $217M | $188M | $155M | $137M | $146M | $171M |
| Total assets | $336M | $280M | $218M | $190M | $157M | $139M | $148M | $173M |
| Long-term debt | $35M | $34M | $14M | $14M | — | — | — | — |
| Total liabilities | $52M | $55M | $33M | $29M | $15M | $16M | $14M | $21M |
| Total equity | $284M | $225M | $186M | $161M | $142M | $124M | $133M | $153M |